Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers Between Academia And Industry column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Pharmaceuticals, and Medical Devices sectors.
HTG gets rights to PROOF Centre's COPD prognostic test
Gene expression profiling firm HTG Molecular Diagnostics Inc. has received exclusive rights to market the non-profit Centre of...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
Chiesi and the Boston-area biotech will co-develop a CRISPR-Cas gene-editing therapy for primary hyperoxaluria type 1. They hope to provide a curative therapy for the rare disease.
Plus deals involving Klotho/Turn, BioLineRx/Hemispherian, Dogwood/Serpin, Harrow/Melt, Gossamer/Respira, Lilly/Prellis, BI/TegMine and more.
The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.
